Advocacy groups warn Trump's pharmaceutical tariffs will spike costs

The administration’s policy aims to force drugmakers to shift production to the United States. According to the executive order, the White House has secured agreements with 13 pharmaceutical companies, with four more expected to follow, involving a total investment of at least $400 billion in domestic manufacturing plants. While some trading partners, including the European Union, Japan, and the United Kingdom, face lower tiered levies between 10% and 15%, the broader policy remains shrouded in secrecy.

Critics contend that the administration is prioritizing corporate profits over patient affordability. Merith Basey, CEO of Patients for Affordable Drugs, warned that the tariffs risk driving up costs for millions of Americans who already struggle to secure necessary medications. Public Citizen’s Peter Maybarduk echoed these concerns, describing the manufacturing commitments as "specious victories" that largely repackage existing industry plans rather than addressing supply chain vulnerabilities. Advocacy groups argue that by shielding drug company profits while using tariffs as leverage to bully other nations, the administration is failing to deliver the promised relief for domestic consumers.